Ironwood licenses European rights to IBS compound to Almirall
This article was originally published in Scrip
Executive Summary
Ironwood Pharmaceuticals could receive $150 million for licensing out the European rights of the investigational compound
| Table |
|---|
Topics
- Therapy Areas
- Gastrointestinal
- Regions
- Europe
- Subjects
- Companies
- Deals
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC001871
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC001871
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.